Edition:
United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

16.30USD
12 Dec 2017
Change (% chg)

$0.05 (+0.31%)
Prev Close
$16.25
Open
$16.25
Day's High
$16.55
Day's Low
$15.80
Volume
761,287
Avg. Vol
168,751
52-wk High
$17.70
52-wk Low
$9.30

Select another date:

Fri, Dec 8 2017

BRIEF-Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals

* LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING Source text : [http://bit.ly/2jz2syj] Further company coverage:

Sucampo weighs sale after fielding takeover interest: Bloomberg

Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

Sucampo weighs sale after fielding takeover interest -Bbg

Dec 7 Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

BRIEF-Sucampo reports Q3 GAAP earnings per share $0.19

* Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S

BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA

* Sucampo Pharmaceuticals announces FDA acceptance of sNDA for amitiza in children with pediatric functional constipation, with priority review designation

BRIEF-Cancer Prevention Pharmaceuticals receives $9.5 mln in additional funding from Sucampo

* Cancer Prevention Pharmaceuticals receives $9.5 million in additional funding from sucampo following phase 3 trial progress

BRIEF-Sucampo Pharmaceuticals and Four Irvington Centre Associates enters into second amendment

* Sucampo Pharmaceuticals - On Sept 5, 2017, Co and Four Irvington Centre Associates, LLC entered into a second amendment to lease agreement- SEC filing

BRIEF-Sucampo reports Q2 GAAP loss per share $3.92

* Q2 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

BRIEF-Sucampo Pharmaceuticals says board voted to increase authorized size of board from six to seven

* Sucampo Pharmaceuticals Inc - On July 15 co's board voted to increase authorized size of board by one, from six to seven Source text: [http://bit.ly/2tgJFdK] Further company coverage:

BRIEF-Sucampo Pharmaceuticals announces issuance of new patent for VTS-270

* Sucampo Pharmaceuticals announces issuance of new patent for VTS-270

Select another date: